Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

NCT02157298 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
266
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AstraZeneca